Patents by Inventor Mitsuru Naiki
Mitsuru Naiki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230302040Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.Type: ApplicationFiled: May 4, 2023Publication date: September 28, 2023Applicants: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD., OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki TANAKA, Hideki YOSHIKAWA, Hideki MOCHIZUKI, Tsuyoshi MURASE, Tsutomu SASAKI, Kousuke BABA, Toru IWAHASHI, Mitsuru NAIKI
-
Patent number: 11679122Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.Type: GrantFiled: May 19, 2022Date of Patent: June 20, 2023Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Hideki Yoshikawa, Hideki Mochizuki, Tsuyoshi Murase, Tsutomu Sasaki, Kousuke Baba, Toru Iwahashi, Mitsuru Naiki
-
Publication number: 20230066066Abstract: A medical sheet has a cell infiltration suppressing action, including a nonwoven fabric formed of fiber containing an aliphatic polyester, and having a porosity of 50 to 90%. The sheet is very useful because it has an excellent neuroprotective and/or nerve regeneration promoting action, which protects nerves by suppressing the infiltration of inflammatory cells such as macrophages and not giving stimulation that adversely affects nerves because body fluids pass therethrough, by winding around a nerve at a peripheral nerve injury site.Type: ApplicationFiled: January 14, 2021Publication date: March 2, 2023Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Takafumi KONISHI, Mitsuru NAIKI, Toshiko UJITA, Hitoshi YAMAMOTO
-
Publication number: 20220273692Abstract: An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.Type: ApplicationFiled: May 19, 2022Publication date: September 1, 2022Applicants: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki TANAKA, Hideki YOSHIKAWA, Hideki MOCHIZUKI, Tsuyoshi MURASE, Tsutomu SASAKI, Kousuke BABA, Toru IWAHASHI, Mitsuru NAIKI
-
Patent number: 11369626Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.Type: GrantFiled: June 22, 2020Date of Patent: June 28, 2022Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Hideki Yoshikawa, Hideki Mochizuki, Tsuyoshi Murase, Tsutomu Sasaki, Kousuke Baba, Toru Iwahashi, Mitsuru Naiki
-
Publication number: 20220079995Abstract: An object of the present invention is to provide an agent for promoting expression of N-acetylgalactosaminyltransferase that contains an extract from inflamed tissues inoculated with vaccinia virus. The present invention demonstrated that the extract from inflamed tissues inoculated with vaccinia virus promotes the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. Thus, the extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract is useful as an agent for promoting the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells.Type: ApplicationFiled: November 26, 2021Publication date: March 17, 2022Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Daisuke SAKAI, Tomoko NAKAI, Mitsuru NAIKI, Yoji SHIBAYAMA
-
Patent number: 11129976Abstract: The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.Type: GrantFiled: February 24, 2017Date of Patent: September 28, 2021Assignees: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki Tanaka, Tsuyoshi Murase, Hideki Yoshikawa, Mitsuru Naiki, Tomonori Matsumoto
-
Publication number: 20210140081Abstract: A non-woven fabric including fibers including an aliphatic polyester that has at least two maximum values in a molecular weight distribution thereof, wherein the fibers have a fiber diameter falling within the range of 100 to 3000 nm. The non-woven fabric of the present invention has excellent biodegradability.Type: ApplicationFiled: July 9, 2019Publication date: May 13, 2021Applicants: NATIONAL INSTITUTE FOR MATERIALS SCIENCE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Koichiro UTO, Mitsuhiro EBARA, Mitsuru NAIKI, Takafumi KONISHI, Hitoshi YAMAMOTO
-
Publication number: 20210008092Abstract: A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.Type: ApplicationFiled: June 22, 2020Publication date: January 14, 2021Applicants: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki TANAKA, Hideki YOSHIKAWA, Hideki MOCHIZUKI, Tsuyoshi MURASE, Tsutomu SASAKI, Kousuke BABA, Toru IWAHASHI, Mitsuru NAIKI
-
Patent number: 10780133Abstract: An object of the present invention is to provide a protective method for liver comprising the administration of an extract from inflamed tissues inoculated with vaccinia virus to a patient who needs the treatment and to provide a liver protective agent, etc. where such an extract is an active ingredient. In the present invention, it has been recognized that, in hepatocytes, activation of NF-B, expression of NF-B target genes, activation of JNK, apoptosis and fat accumulation can be inhibited or suppressed. The agent containing the extract as an active ingredient is a drug exhibiting less adverse action and high safety. Accordingly, the present invention provides very useful protective method for liver and liver protecting agent.Type: GrantFiled: August 7, 2015Date of Patent: September 22, 2020Assignees: NIPPON ZOKI PHARMACEUTICALS CO., LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Ekihiro Seki, Koichi Masuda, Mitsuru Naiki
-
Patent number: 10711292Abstract: The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.Type: GrantFiled: September 18, 2015Date of Patent: July 14, 2020Assignees: NIKKON ZOKI PHARMACEUTICAL CO., LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Koichi Masuda, Mitsuru Naiki
-
Publication number: 20190255121Abstract: An object of the present invention is to provide an agent for promoting expression of N-acetylgalactosaminyltransferase that contains an extract from inflamed tissues inoculated with vaccinia virus. The present invention demonstrated that the extract from inflamed tissues inoculated with vaccinia virus promotes the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. Thus, the extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract is useful as an agent for promoting the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells.Type: ApplicationFiled: February 19, 2019Publication date: August 22, 2019Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Daisuke SAKAI, Tomoko NAKAI, Mitsuru NAIKI, Yoji SHIBAYAMA
-
Publication number: 20190175894Abstract: The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.Type: ApplicationFiled: February 24, 2017Publication date: June 13, 2019Applicants: OSAKA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroyuki TANAKA, Tsuyoshi MURASE, Hideki YOSHIKAWA, Mitsuru NAIKI, Tomonori MATSUMOTO
-
Patent number: 10004716Abstract: A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.Type: GrantFiled: March 19, 2015Date of Patent: June 26, 2018Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Mitsuru Naiki, Takumi Numazawa, Hiroki Fujisawa
-
Publication number: 20170224738Abstract: An object of the present invention is to provide a protective method for liver comprising the administration of an extract from inflamed tissues inoculated with vaccinia virus to a patient who needs the treatment and to provide a liver protective agent, etc. where such an extract is an active ingredient. In the present invention, it has been recognized that, in hepatocytes, activation of NF-B, expression of NF-B target genes, activation of JNK, apoptosis and fat accumulation can be inhibited or suppressed. The agent containing the extract as an active ingredient is a drug exhibiting less adverse action and high safety. Accordingly, the present invention provides very useful protective method for liver and liver protecting agent.Type: ApplicationFiled: August 7, 2015Publication date: August 10, 2017Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Ekihiro SEKI, Koichi MASUDA, Mitsuru NAIKI
-
Publication number: 20170135985Abstract: A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.Type: ApplicationFiled: March 19, 2015Publication date: May 18, 2017Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Mitsuru NAIKI, Takumi NUMAZAWA, Hiroki FUJISAWA
-
Patent number: 9557327Abstract: An object of the present invention is to provide DNA which regulates the expression of miR-140, a reporter vector which contains the DNA, cells and animals into which the reporter vector is introduced and a screening system for drugs which control the expression of miR-140 and is also to contribute in the development of new therapeutic agents for cartilage diseases such as osteoarthritis and intervertebral disk degeneration using the screening system. The DNA sequence according to the present invention is able to express any gene in a site where miR-140 is expressed and, in addition, it is also able to be utilized for screening a drug which regulates the expression of miR-140. Moreover, the drug that is selected by the screening system of the present invention is expected as a therapeutic agent for cartilage diseases accompanied by abnormality of cartilage.Type: GrantFiled: April 2, 2013Date of Patent: January 31, 2017Assignees: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Asahara, Satoshi Yamashita, Mitsuru Naiki, Kentaro Abe
-
Patent number: 9428477Abstract: The present invention relates to a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical agent containing the compound as an active ingredient. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt, which is the compound of the present invention, is specifically represented by the general formula (I): wherein X is a substituent such as a 1-pyrrolidyl, a 3-thiazolizyl, or a piperidino, and the compound is highly useful as a pharmaceutical agent, such as a prophylactic or therapeutic agent for a peripheral nerve disorder induced by administration of an anticancer agent, a prophylactic or therapeutic agent for neurodegenerative diseases or mental diseases such as dementia, Alzheimer's disease, Parkinson's disease, diabetic neuropathy, depression, glaucoma, or autistic disorder spectrum, a therapeutic or repairing agent for spinal cord injury, analgesics against various pain diseases, or the like.Type: GrantFiled: April 26, 2013Date of Patent: August 30, 2016Assignees: NIPPON ZOKI PHARMACEUTICAL CO., LTD., NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTEInventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Kunihiko Higashiura
-
Patent number: 9365533Abstract: A novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient is provided. The coumarin derivative or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sGAG) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis.Type: GrantFiled: September 20, 2013Date of Patent: June 14, 2016Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Mitsuru Naiki, Tomoyuki Okada, Kazuyoshi Sawada, Takashi Ogino
-
Publication number: 20160010135Abstract: The synthesis of collagen and proteoglycan in chondrocytes, such as intervertebral disc cells, articular chondrocytes and meniscal cells is promoted by administration of an extract from inflamed tissue inoculated with vaccinia virus.Type: ApplicationFiled: September 18, 2015Publication date: January 14, 2016Applicants: NIPPON ZOKI PHARMACEUTICAL CO., LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Koichi MASUDA, Mitsuru NAIKI